BioVie BIVI 深 沪
等待开盘 09-17 09:30:00 美东时间
1.78
+0.030
+1.71%
华盛通- 最 高1.81
- 今 开1.76
- 成交量 24.28万股
- 最 低 1.69
- 昨 收 1.75
- 总市值 1518.54万
- 52周最高 3.79
- 市盈率 静 --
- 换手率 2.85%
- 52周最低 0.82
- 委 比 -33.33%
- 总股本 853.11万
- 历史最高 4609.80
- 量 比 1.14
- 振 幅 6.86%
- 历史最低 0.82
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With BioVie Stock on Tuesday?
Clinical-stage biopharmaceutical firm BioVie Inc. (NASDAQ:BIVI) stock is trading lower after the company shared topline results from its Phase 2 ADDRESS-LC study evaluating bezisterim in Long COVID patients. Pre-specified subgroup analyses submitted to the FDA before unblinding showed that participa...
09-16 00:21
BioVie Enters Sales Agreement With Alliance Global Partners For Up To $6,464,341 Of Stock
On September 11, 2026, BioVie Inc., a Nevada corporation (the "Company"), entered into a sales agreement (the "Sales Agreement") with A.G.P./Alliance Global Partners (the "Agent"), pursuant to which the Company may issue and sell from time to time, to or through the Agent, shares of the Company’s Cl...
09-14 18:13
宝莱特新注册《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权
证券之星消息，近日宝莱特（300246）新注册了《BioView C100系列麻醉视频喉镜主控软件V1.0》项目的软件著作权。今年以来宝莱特新注册软件著作权9个。
09-09 04:25
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
BioVie shares are trading higher after the company announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed.
08-31 23:29
BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
BioVie Inc. has completed the last patient visit for its ADDRESS-LC Phase 2 trial evaluating bezisterim for treating Long COVID neurological symptoms. Topline results are expected by September 2026. The study, funded by a $13.13 million grant from the U.S. Department of War, aims to assess bezisterim's efficacy in reducing symptoms like fatigue and brain fog. Bezisterim, an investigational drug targeting neuroinflammation, has shown promise in Pa...
08-31 12:00
Why Webull Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of Webull Corp (NASDAQ:BULL) rose sharply in pre-market trading after the company reported better-than-expected second-quarter financial results. Webull reported second-quarter revenue of $198.83 million, beating estimates of $181.26 million, according to Benzinga Pro. The brokerage platform ...
08-20 16:53
BioVie Q4 EPS $(0.70) Up From $(1.42) YoY
BioVie (NASDAQ:BIVI) reported quarterly losses of $(0.70) per share. This is a 50.7 percent increase over losses of $(1.42) per share from the same period last year.
08-13 18:29
Why Eva Live Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Eva Live Inc (NASDAQ:GOAI) rose sharply in pre-market trading after the company signed a Letter of Intent to acquire a 51% controlling stake in Airbeam Wireless Technologies for $16 million. Eva Live shares jumped 16.4% to $2.85 in pre-market trading. Here are some other stocks moving in p...
07-20 16:56
BioVie Announces Full Enrollment Of ADDRESS-LC Phase 2 Trial Evaluating Drug Candidate Bezisterim For Treatment Of Neurological Symptoms Of Long COVID
-Topline Data Release Targeted Late Summer 2026-CARSON CITY, Nev., May 26, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for
05-26 20:06
BioVie Announces Completion Of Last Patient Evaluation Visit In The SUNRISE-PD Phase 2 Trial Evaluating Its Drug Candidate Bezisterim In Early Stage Parkinson's Disease
"With this last patient's treatment visit completed, our team will start the study closeout process, and the Company plans announce topline results in Q3," said Cuong Do, BioVie's President and CEO. "This trial was
05-18 20:02
